August 29, 2020, Food and Drug Administration Headquarters, White Oak, Maryland. Andrew Kelly/Reuters
The Food and Drug Administration (FDA) on October 16 announced the first batch of drugs to undergo expedited review under the Secretary’s National Priority Voucher (CNPV) testing program.
The FDA has stated that “voucher recipients will receive a decision within one to two months of submitting a complete drug or biologic application,” which is much faster than previous schedules.
There was a problem loading this article. Please enable JavaScript or use a different browser. If the issue persists, please visit our Help Center.
